Physician profile
James N Odea
NPI 1013165174
$16,871.22
in general payments reported to CMS, 2019-2025
44 companies · $7,184 in 2025
The $7,184 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $988 · 2021: $1,652 · 2022: $3,370 · 2023: $1,821 · 2024: $765 · 2025: $7,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,005 · Food and Beverage: $3,522 · Travel and Lodging: $2,237 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,005.00 |
| Food and Beverage | $3,522.46 |
| Travel and Lodging | $2,237.33 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $6,691.33 | 2024-2025 | Biofire Spotfire Respiratory/Sore Throat (R/St) Panel, Biofire Spotfire Control Station |
| Medtronic, INC. | $2,070.56 | 2022-2024 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $1,734.35 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $941.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $740.53 | 2021-2025 | |
| Novo Nordisk INC | $660.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $639.24 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.43 | 2019-2025 | Jardiance |
| Pfizer INC. | $439.68 | 2019-2023 | |
| Abbott Laboratories | $265.66 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Supernus Pharmaceuticals, INC. | $178.50 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $159.28 | 2019-2023 | Belsomra, Steglatro, Gardasil 9 |
| Amgen INC. | $148.15 | 2019-2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $131.76 | 2021 | |
| Gilead Sciences, INC. | $128.13 | 2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $126.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.11 | 2019-2023 | Xifaxan |
| Dexcom, INC. | $99.03 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $93.78 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $76.44 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $76.39 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $74.79 | 2021-2022 | |
| Antares Pharma, INC. | $72.34 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Beta Bionics, INC. | $67.30 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Daiichi Sankyo INC. | $56.70 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $43.19 | 2022 | |
| Corcept Therapeutics | $40.64 | 2025 | Korlym |
| Upsher-Smith Laboratories LLC | $38.01 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $37.82 | 2022-2023 | Rexulti |
| Allergan, INC. | $37.35 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $36.48 | 2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $35.92 | 2020-2021 | |
| Eisai INC. | $32.87 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.10 | 2023 | Gvoke Hypopen |
| Axonics, INC. | $21.94 | 2023 | Axonics |
| Biogen, INC. | $21.84 | 2021 | |
| Lundbeck LLC | $21.81 | 2024 | Rexulti |
| Grifols USA, LLC | $19.57 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.15 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $14.72 | 2022 | |
| Inari Medical, INC. | $13.46 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Avanir Pharmaceuticals, INC. | $13.35 | 2020 | |
| Dynavax Technologies Corporation | $11.55 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Odea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.